Taewoong Choi

Overview

Based on my prior experience in basic/translational immunology research and clinical hematopoietic stem cell transplantation, I am interested in early phase clinical protocols for novel immunotherapy of hematologic malignancies.

Positions

Assistant Professor of Medicine in the School of Medicine

2021 School of Medicine

Member of the Duke Cancer Institute in the School of Medicine

2019 School of Medicine

Education

M.D., Seoul National University (South Korea) 2002

2002 Seoul National University (South Korea)

Internship and Residency in Internal Medicine, St. Luke's Memorial Hospital Center 2009 - 2012

2012 St. Luke's Memorial Hospital Center

Hematology/Oncology Fellowship, University of Pittsburgh, School of Medicine 2012 - 2015

2015 University of Pittsburgh, School of Medicine

BMT Fellowship, Stanford University, School of Medicine 2015 - 2016

2016 Stanford University, School of Medicine

Postdoctoral Research Fellow on T32 Training Grant, Stanford University, School of Medicine 2016 - 2017

2017 Stanford University, School of Medicine

Clinical Trials

Celgene: GC-LTFU-001 (Multiple Myeloma)

Publications, Grants & Awards

Grants (7)
Awards (1)
Academics Articles (26)
Conference Pages (19)

Showing 1 - 5 of 7

BMT CTN 1902: Phase II Multicenter Trial of anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for Multiple Myeloma Patients with Sub-Optimal Response After Autologous Hematopoietic Cell Transplantation and Maintenance Lenalidomi

2022-2027National Marrow Donor Program

Long Term Follow-up Protocol for Subjects Treated with Gene-Modified T Cells

2021-2026Celgene Corporation

A Phase I, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 as a single agent in relapsed or refractory hematological malignancies and in combgination with Daratumumab as a Salvage Regimen for Multiple Myeloma

2020-2024Nektar Therapeutics

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of BB2121 Versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KARMMa-3)

2019-2024Celgene Corporation

An Exploratory Phase 1/2 Trial to Determine Recommended Phase 2 Dose (RP2D), Safety and Preliminary Efficacy of bb2121 (Ide-cel) Combinations in Subjects with Refractory/Relapsed Multiple Myeloma (KarMMa-7)

2022-2023Celgene Corporation

Offices & Contact

2400 Pratt St Suite 5000
Durham, NC
27710

DUMC Box 3961
Durham, NC
27710